Bristol Myers to pay up to $1.56 billion to develop, sell Agenus’s cancer therapy

imageStock Markets19 minutes ago (May 19, 2021 06:32AM ET)

(C) Reuters. The logo of U.S. drugmaker Bristol Myers Squibb. via REUTERS

(This May 18 story corrects payment value in headline and first paragraph to $1.56 billion from $1.38 billion)

(Reuters) – Drugmaker Bristol Myers (NYSE:BMY) Squibb will pay biotech firm Agenus (NASDAQ:AGEN) Inc up to $1.56 billion to exclusively develop and commercialize its experimental cancer drug, AGEN1777, the companies said on Tuesday.

The drug candidate, primarily being tested to improve anti-tumor activity, will also be studied and developed by Bristol Myers for immuno-oncology treatments including non-small cell lung cancer, which accounts for about 85% of lung cancer cases globally.

Bristol Myers has been betting on sales of its Opdivo drug to treat such cancers, but that market is currently dominated by Merck & Co’s rival treatment Keytruda.

Agenus will receive up to $1.36 billion in development, regulatory and commercial milestones in addition to double-digit royalties on net product sales. It will receive an upfront payment of $200 million. (

The biotech company will retain options to conduct clinical studies under the development plan, and to test it in combination with certain other pipeline assets, and will co-promote AGEN1777 in the United States after commercialization.

Agenus plans to file application to begin human trials for the therapy with the U.S. Food and Drug Administration in the second quarter of this year, the company said.

Bristol Myers to pay up to $1.56 billion to develop, sell Agenus’s cancer therapy

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.